At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 354 enrolled
Drug / intervention
Secukinumab 300 mg +2 morebiological
Likely dose
Secukinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg and 150 mg Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (GCAptAIN)
In Brief
A Phase 3 clinical trial evaluating Secukinumab 300 mg, Placebo, and 1 other intervention for Giant Cell Arteritis (GCA). Completed, enrolled 354 participants across 104 sites in 27 countries.
Detailed Summary
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGiant Cell Arteritis (GCA)
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hungary, Israel, Italy, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartOct 2021
Primary CompletionApr 2025
Study CompletionFeb 2026
TodayJul 2026
First PostedJun 18, 2021
Enrollment StartOct 6, 2021
Primary CompletionApr 11, 2025
Study CompletionFeb 18, 2026
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.0 years ago
Interventions
Secukinumab 300 mgbiological
Secukinumab 300 mg
Placeboother
Placebo
Secukinumab 150 mgbiological
Secukinumab